Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Hepatol Res. 2007 Nov;37(11):923-31. doi: 10.1111/j.1872-034X.2007.00150.x. Epub 2007 Jul 4.
Serum antinuclear antibodies (ANA) are occasionally noted in patients with non-alcoholic steatohepatitis (NASH). We examined the significance of ANA in NASH.
We compared clinicopathological features in patients with ANA-positive NASH (n = 35) and ANA-negative NASH (n = 36). Inflammatory cell profiles and the distribution of oxidative stress markers were also examined immunohistochemically.
ANA-positive NASH was significantly associated with female gender (P = 0.005), high degree of portal inflammation (P = 0.039), interface activity (P = 0.036) and hepatocellular ballooning (P = 0.0008). In addition, ANA of high titer (320-fold or more) was significantly associated with the histological grade and stage of NASH (P = 0.02). The degree of steatosis wais rather mild in the high-titer ANA group(P = 0.01). The analysis of inflammatory cell profiles revealed that CD3-positive T cells were predominant and plasma cells were rather few in the portal area and hepatic lobules in both ANA-positive and ANA-negative groups. There was no difference in the distribution of oxidative stress markers between ANA-positive and ANA-negative groups.
These findings suggest that the presence of ANA may be related to the progression of NASH and that a different type of autoimmune mechanism may be involved in the pathogenesis of NASH with ANA, compared to the pathogenesis of autoimmune hepatitis.
血清抗核抗体(ANA)偶尔在非酒精性脂肪性肝炎(NASH)患者中被发现。我们研究了 ANA 在 NASH 中的意义。
我们比较了 ANA 阳性 NASH(n = 35)和 ANA 阴性 NASH(n = 36)患者的临床病理特征。还通过免疫组织化学检查了炎症细胞谱和氧化应激标志物的分布。
ANA 阳性 NASH 与女性(P = 0.005)、门静脉炎症程度高(P = 0.039)、界面活动(P = 0.036)和肝细胞气球样变(P = 0.0008)显著相关。此外,高滴度(320 倍或更高)ANA 与 NASH 的组织学分级和分期显著相关(P = 0.02)。高滴度 ANA 组的脂肪变性程度较轻(P = 0.01)。炎症细胞谱分析表明,ANA 阳性和 ANA 阴性组的门脉区和肝小叶均以 CD3 阳性 T 细胞为主,浆细胞较少。ANA 阳性和 ANA 阴性组之间氧化应激标志物的分布无差异。
这些发现表明,ANA 的存在可能与 NASH 的进展有关,与自身免疫性肝炎相比,ANA 可能涉及 NASH 发病机制的一种不同的自身免疫机制。